Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - calcium carbonate; disodium etidronate -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

eris pharmaceuticals (australia) pty ltd - calcitriol -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

actavis pty ltd - calcitriol -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

scentia pharmaceuticals pty ltd - calcitriol -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - calcitriol -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - calcitriol -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - calcitriol -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: fractionated coconut oil; butylated hydroxyanisole; butylated hydroxytoluene; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; iron oxide red; iron oxide yellow; titanium dioxide - calcitriol is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture.,calcitriol is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss.,calcitriol is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - calcitriol -

Marekani - Kiingereza - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - predialysis patients calcitriol oral solution is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. dialysis patients calcitriol oral solution is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol oral solution administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. hypoparathyroidism patients calcitriol oral solution is also indicated in the management of hypocalcemia and its clinical manif